Annual Report: Eli Lilly
Eli Lilly Annual Report 2018
This report is acknowledging Eli Lilly's 2018 FDA approved drug galcanezumab, also known as CGRP-inhibitor that will be marketed under the name Emgality. This medicine is for the treatment of chronic migraines and cluster headaches. 
“We’re trying to change the frontiers of what’s possible in medicine. 
Our vision is to change patients’ expectations – to provide a new sense of hope for people suffering from some of the world’s most debilitating diseases.”

“Even getting excited about things can be a trigger. 
You can practically guarantee that any event of special occasion that I look forward to will lead to some degree of migraine.” ​​​​​​​
“I cannot bear light or noise. I typically listen to music when I want to relax. 
However, when an attack comes on I have to be in complete silence.”
“Even going to the grocery store is hard. 
I am constantly looking at everything in the store and this causes me to become dizzy.”
Annual Report: Eli Lilly
2
60
0
Published:

Annual Report: Eli Lilly

2
60
0
Published:

Tools

Creative Fields